CRGX
Income statement / Annual
Last year (2023), CARGO Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, CARGO Therapeutics, Inc. Common Stock's net income was -$98.15 M.
See CARGO Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.69 M |
$1.44 M |
$147,000.00 |
| Gross Profit |
-$3.69 M |
-$1.44 M |
-$147,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
| Research and Development
Expenses |
$75.79 M
|
$29.37 M
|
$4.46 M
|
| General & Administrative
Expenses |
$20.92 M
|
$5.40 M
|
$1.52 M
|
| Selling & Marketing
Expenses |
-$3.69 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$17.23 M
|
$5.40 M
|
$1.52 M
|
| Other Expenses |
$0.00 |
-$22,000.00 |
$127,000.00 |
| Operating Expenses |
$93.02 M |
$34.77 M |
$5.98 M |
| Cost And Expenses |
$96.71 M |
$34.77 M |
$5.98 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.60 M |
$4.94 M |
$0.00 |
| Depreciation &
Amortization |
$3.69 M
|
$1.44 M
|
$147,000.00
|
| EBITDA |
-$93.02 M
|
-$33.35 M
|
-$5.70 M
|
| EBITDA Ratio |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.44 M
|
-$6.18 M
|
$127,000.00
|
| Income Before Tax |
-$98.15 M |
-$40.95 M |
-$5.85 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$4.92 M |
$127,000.00 |
| Net Income |
-$98.15 M |
-$40.95 M |
-$5.85 M |
| Net Income Ratio |
0 |
0 |
0 |
| EPS |
-2.38 |
-2.13 |
-0.3 |
| EPS Diluted |
-2.38 |
-2.13 |
-0.3 |
| Weighted Average Shares
Out |
$41.21 M
|
$19.23 M
|
$19.47 M
|
| Weighted Average Shares
Out Diluted |
$41.21 M
|
$19.23 M
|
$19.47 M
|
| Link |
|
|
|
